Filtrer vos résultats
- 2
- 2
- 2
- 1
- 1
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or bothAmerican Heart Journal, 2020, 222, pp.166-173. ⟨10.1016/j.ahj.2020.01.015⟩
Article dans une revue
hal-02870366v1
|
|||
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA RegistryEuropean Heart Journal - Cardiovascular Pharmacotherapy, 2022, ⟨10.1093/ehjcvp/pvac028⟩
Article dans une revue
hal-03675513v1
|